Illumina, Inc. (ILMN) Shares Sold by Bamco Inc. NY
Bamco Inc. NY lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 0.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 444,335 shares of the life sciences company’s stock after selling 4,222 shares during the quarter. Bamco Inc. NY owned approximately 0.30% of Illumina worth $88,512,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of ILMN. Winslow Capital Management LLC purchased a new stake in Illumina during the 2nd quarter worth about $211,584,000. HPM Partners LLC increased its holdings in Illumina by 29,103.8% during the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after purchasing an additional 749,424 shares during the period. Fred Alger Management Inc. increased its holdings in Illumina by 611.9% during the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after purchasing an additional 548,030 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the period. Finally, Capital World Investors increased its holdings in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the period. Hedge funds and other institutional investors own 91.75% of the company’s stock.
Several equities research analysts have weighed in on the company. Goldman Sachs Group restated a “neutral” rating and set a $200.00 price target on shares of Illumina in a report on Tuesday, September 26th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Canaccord Genuity restated a “buy” rating and set a $230.00 price target (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target on the stock in a report on Tuesday, December 5th. Finally, Argus upped their price target on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $201.98.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.97 EPS. equities research analysts predict that Illumina, Inc. will post 3.75 earnings per share for the current year.
In related news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $203.27, for a total value of $4,065,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,421 shares of company stock valued at $28,489,101. Insiders own 0.89% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.